metformin
Drug3 years treatment duration
Other names: Glucophage
NCT Number: NCT01483560
The trial is conducted in the United Kingdom (UK), Australia, Canada, Denmark and the Netherlands. The aim is to test whether 3 years treatment with metformin added to titrated insulin therapy (towards target HbA1c 7.0%/53 mmol/mol) reduces atherosclerosis, as measured by progression of carotid intima-media thickness (cIMT), in adults with confirmed type 1 diabetes aged 40 years and over at increased risk for cardiovascular disease.
Looking for future studies?
Notify Me40 year and older
All sexes
Interventional
Phase 3
Royal Melbourne Hospital, Melbourne, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
AND 3 or more of the following ten CardioVascular Disease (CVD) risk factors:
Exclusion criteria
3 years treatment duration
Other names: Glucophage
3 years duration
Time frame: 0, 12 months, 24 months, 36 months
Progression of averaged mean far wall common carotid artery intima media thickness IMT (mean cIMT) measured using B mode ultrasonography with a 7.0 MHz or higher broadband linear array transducer and concurrent recording of 3-lead electrocardiogram (ECG). Longitudinal images of the common carotid artery will be obtained at anterior, lateral and posterior angles at baseline, 12, 24 and 36 months using Meijer's arc to standardize the transducer angle.
Time frame: Baseline, Year 3
Measured in accredited local laboratories participating in DCCT-aligned quality control programmes.
Time frame: Baseline, Year 3
mmol/L Centrally assayed at the University of Glasgow
Time frame: Baseline, Year 1, Year 2, Year 3
Number of participants developing new microalbuminuria; change in absolute concentration Calculated using the MDRD equation1 based on creatinine measured in accredited local laboratories
Time frame: Baseline, Year 3
Two color 45° field retinal photographs (fields 1 and 2) from each eye at 0 and 36 months graded at the University of Wisconsin Ocular Epidemiology Reading Center (OERC) using the modified Airlie House classification scheme and the Early Treatment Diabetic Retinopathy Severity scale.
Time frame: Baseline, Year 1, Year 2, Year 3
Measured at sites using calibrated weighing scales
Time frame: Baseline, Year 1, Year 2, Year 3
Units/ kg body weight Extracted by study nurses from the Study Diary and reported on the study CRF using dedicated fields
Time frame: Baseline, Year 1, Year 3
In some centres (Arbitrary units) Reactive Hyperaemia Index using the ENDOPAT device (Itamar, Israel)
University of Glasgow
Other
Phase 3 Study of Metformin in Adults With Type 1 Diabetes
Acronym: REMOVAL
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06236256
Autoimmune Diseases, Diabetes Mellitus
Ramat Gan, Israel
View Trial DetailsNCT07711275
Autoimmune Diseases, Diabetes Mellitus
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT03938324
Anemia, Anemia, Hemolytic
Durham, North Carolina, United States
View Trial DetailsNCT07090824
Autoimmune Diseases, Diabetes Mellitus
Palo Alto, California, United States
View Trial Details